THE ROUNDUP

FDA Seeks 'Little' Information

Clare Kittredge
Jun 1, 2006

The US Food and Drug Administration plans to hold a public meeting this fall to hear from nanotechnology researchers about new developments and challenges involving the use of nanotech materials in FDA-regulated products. "The FDA needs to take a position to help guide product development that's on the cusp of happening," says Michael Arbige, senior vice president of technology for Genencor, a Palo Alto, Calif.-based biotech company that uses nanotech to develop products for the healthcare and biotech industries. "We're very anxious to hear the feedback."

Ted Sullivan, an analyst for New York City-based Lux Research, estimates the market for the use of nanotechnology in drug delivery systems at $1.3 billion for 2005, with a 35% annual growth rate projected for the next five years. "Nanotechnology is also being used in therapeutics," says Sullivan. He points to examples including Berlin-based MagForce Nanotechnologies, which is testing magnetic nanoparticles to burn away...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?